Alejandro Ruiz-Patiño

Alejandro Ruiz-Patiño

Auto-generated profile, based on publicly available information

Alejandro Ruiz-Patiño

Clinical Genetics Group, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
RRRafael Ruiz-Gaviria
Rafael Ruiz-Gaviria
IBIvan Baracaldo
Ivan Baracaldo
CCCamilo Castañeda
Camilo Castañeda
ARAlejandro Ruiz-Patiño
Alejandro Ruiz-Patiño
AAAndres Acosta-Hernandez
Andres Acosta-Hernandez
DRDiego Rosselli
Diego Rosselli

11 June 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
COCamila Ordóñez-Reyes
Camila Ordóñez-Reyes
Juan Esteban Garcia-RobledoJuan Esteban Garcia-Robledo
Juan Esteban Garcia-Robledo
DODiego Fernando Chamorro Ortiz
Diego Fernando Chamorro Ortiz
APAndrés Felipe Mosquera Paternina
Andrés Felipe Mosquera Paternina
LSLiliana Sussmann
Liliana Sussmann
ACAndres Cardona
Andres Cardona
Immunotherapy has redefined the treatment of cancer patients and it is constantly generating new advances and approaches. Among the multiple options of immunotherapy, bispecific antibodies (bsAbs) represent a novel thoughtful approach. These drugs integrate the action of the immune system in a strategy to redirect the activation of innate and adaptive immunity toward specific antigens and specific tumor locations. Here we discussed some basic aspects of the design and function of bsAbs, their main challenges and the state-of-the-art of these molecules in the treatment of hematological and solid malignancies and future perspectives.

24 July 2020 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
ARAlejandro Ruiz‐Patiño
Alejandro Ruiz‐Patiño
FBFeliciano Barrón
Feliciano Barrón
ACAndres Cardona
Andres Cardona
LCLuis Corrales
Luis Corrales
LMLuis Mas
Luis Mas
TCThe CLICaP
The CLICaP
Background: The intestinal microbiota is an important factor in modulating immune‐mediated tumor cell destruction. Alterations in the microbiome composition have been linked to reduced efficacy of immune checkpoint inhibitor (ICI) therapies. Therefore, antibiotic treatment (ATB), which modifies the diversity of the gut bacteria populations, could lead to a reduced efficacy of ICI treatments.Methods: This was a retrospective cohort study. Patients with advanced non‐small cell lung cancer (NSCLC) treated with anti‐programmed cell death ligand‐1 (PD‐L1) alone, or in combination in three different countries in Latin America were included. After identification, patients were placed into three groups: Non‐ATB exposed (no‐ATB), exposed within 30 days of the first dose of ICI (pre‐ICI ATB) and patients receiving ATB concomitantly with ICI (ICI‐ATB). Progression‐free survival (PFS), overall survival (OS) and response rates to treatment with ICI were assessed.Results: A total of 140 patients were included, of which 32 patients (23%) received ATB treatment. The most common ATB types were fluoroquinolones and B‐lactams. No differences in survival according to antibiotic type were identified. Median OS in patients not exposed to ATB was 40.6 months (95% CI: 32–67.7), compared with 20.3 months (95% CI: 12.1‐non‐reached [NR]) for patients with pre‐ICI ATB treatment and 24.7 months (95% CI: 13‐NR) for patients treated with ATB concomitantly with ICI. There were no significant differences in terms of PFS, or response rates across all treatment groups.Conclusions: Antibiotic treatment was associated with reduced OS in Hispanic patients with NSCLC treated with ICIs.

1 April 2018 in Journal of Surgical Research
Verified
Journal Article
Closed access
ARAlejandro Ruiz-Patiño
Alejandro Ruiz-Patiño
SRSamuel Rey
Samuel Rey
GMGerman Molina
German Molina
LDLuis Carlos Dominguez
Luis Carlos Dominguez
SRSaul Rugeles
Saul Rugeles

31 January 2022 in Therapeutic Advances in Respiratory Disease
Verified
Journal Article
Open access
Juan Esteban Garcia-RobledoJuan Esteban Garcia-Robledo
Juan Esteban Garcia-Robledo
RRRafael Rosell
Rafael Rosell
ARAlejandro Ruíz-Patiño
Alejandro Ruíz-Patiño
CSCarolina Sotelo
Carolina Sotelo
OAOscar Arrieta
Oscar Arrieta
ACAndres Cardona
Andres Cardona
Non-small-cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic management has advanced to identify various critical oncogenic mutations that promote lung cancer tumorigenesis. Subsequent studies have developed targeted therapies against these oncogenes in the hope of personalized treatment based on the tumor’s molecular genomics. This review presents a comprehensive review of the biology, new therapeutic interventions, and resistance patterns of two well-defined subgroups, tumors with KRAS and MET alterations. We also discuss the status of molecular testing practices for these two key oncogenic drivers, considering the progressive introduction of next-generation sequencing (NGS) and RNA sequencing in regular clinical practice.

22 November 2021 in Translational Oncology
Verified
Journal Article
Open access
ARAlejandro Ruiz-Patiño
Alejandro Ruiz-Patiño
JRJuly Rodríguez
July Rodríguez
ACAndres Cardona
Andres Cardona
JÁJenny Ávila
Jenny Ávila
PAPilar Archila
Pilar Archila
RRRafael Rosell
Rafael Rosell
The KRAS exon 2 p. G12C mutation in patients with lung adenocarcinoma has been increasing in relevance due to the development and effectiveness of new treatment medications. Studies around different populations indicate that regional variability between ethnic groups and ancestries could play an essential role in developing this molecular alteration within lung cancer. In a prospective and retrospective cohort study on samples from lung adenocarcinoma from 1000 patients from different administrative regions in Colombia were tested for the KRAS p.G12C mutation. An analysis of STR populations markers was conducted to identify substructure contributions to mutation prevalence. Included were 979 patients with a national mean frequency for the KRAS exon 2 p.G12C mutation of 7.97% (95%CI 6.27–9.66%). Variation between regions was also identified with Antioquia reaching a positivity value of 12.7% (95%CI 9.1–16.3%) in contrast to other regions such as Bogota DC (Capital region) with 5.4% (2.7–8.2%) and Bolivar with 2.4% (95%CI 0–7.2%) (p-value = 0.00262). Furthermore, Short tandem repeat population substructures were found for eight markers that strongly yielded association with KRAS exon 2 p.G12C frequency reaching an adjusted R2 of 0.945 and a p-value of < 0.0001. Widespread identification of KRAS exon 2 p.G12C mutations, especially in cases where NGS is not easily achieved is feasible at a population based level that can characterize regional and national patterns of mutation status. Furthermore, this type of mutation prevalence follows a population substructure pattern that can be easily determined by population and ancestral markers such as STR.